Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

First FDA-Approved Preservative-Free Prescription Eye Drop Available in Multidose Bottle

By Allergan plc | March 22, 2017

(Credit: Allergan)

Allergan announces availability of Restasis MultiDose (Cyclosporine Ophthalmic Emulsion) 0.05% — the first FDA-approved preservative free prescription eye drop available in a multidose bottle.

Allergan plc announced the availability of Restasis MultiDose, which is the same preservative-free Restasis formulation, but now offered in a multidose bottle. Restasis is the first and only prescription medication FDA-approved to help patients with a type of chronic dry eye make more of their own tears.

Restasis MultiDose is the first and only FDA-approved preservative-free, prescription eye drop in the U.S. to be available in a multidose bottle. Restasis was accessible only in single-use vials, since its launch in 2003 until now.

Restasis helps increase your eyes’ natural ability to produce tears, which may be reduced by inflammation due to chronic dry eye. Restasis did not increase tear production in patients using anti-inflammatory eye drops or tear duct plugs.

“Since Restasis MultiDose is the only FDA-approved preservative-free prescription eye drop in the U.S. to be offered in a multidose bottle, patients now have a choice of a multidose bottle or single-use vials,” said Neda Shamie, M.D., of Advanced Vision Care, in Los Angeles, CA.

Restasis MultiDose is designed with a patented unidirectional valve and air filter technology. The new multi-dose bottle uses less plastic than a package of single-use vials and will be available for the same price.   

“We are continuously looking to improve patient care through state-of-the-art product engineering, and Restasis MultiDose reflects that commitment,” said David Nicholson, Chief R&D Officer at Allergan.  “This new multidose bottle is designed to maintain the preservative-free formulation.”

Aptar Pharma supplies the patented Ophthalmic Squeeze Dispenser, the first U.S. FDA-approved multidose delivery system to handle prescription eye treatment formulations without any preservatives.

(Source: PR Newswire; Business Wire)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE